Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Stock Information for Autolus Therapeutics plc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Autolus Therapeutics to Participate in Upcoming Investor Conference
Autolus Therapeutics Receives Prix Galien UK Award
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.